Research Resources

Provide resources to make datasets from existing and legacy clinical research studies on AD and related dementias widely accessible…

Provide support to establish/improve the interoperability among relevant biomedical data repositories.…

Increase transparency in reporting and reproducibility of research findings by incentivizing and enforcing rapid sharing…

Enable access to data and associated biosamples and biomarkers from completed, ongoing and future, federally and privately funded clinical trials...

Accelerate independent evaluation of research findings by mandating the open distribution of publicly and privately/philanthropically funded computational and experimental research tools...

Democratize the use of large scale molecular and clinical data by building computational infrastructure for sustainable data storage...

Develop data and resource infrastructures to support management and collaborative analysis of diverse resources from FTD basic science and clinical studies.

Improve rigor, reproducibility, and translatability of discovery research.

Develop a common Alzheimer’s disease research ontology...

Collaboration to advance biomarkers and therapy development for AD/ADRD

Large international collaborations aimed at overcoming barriers to sharing of human data

Convene an advisory meeting focused on facilitating public-private partnerships aimed at accelerating the development and test of effective therapies for AD treatment and prevention...

Convene meetings of the working groups for (i) Rapid Data Sharing and Analysis, (ii) Enabling Bidirectional Translation in AD drug development, (iii) Eliminating IP barriers for Target Validation...

Develop partnerships to support novel/disruptive science that would incentivize students and early-career investigators to adopt a collaborative approach...

Develop partnerships that expand the precompetitive space through clinical proof of concept mechanism to accelerate translational learning...

Develop a partnership among key stakeholders to implement the sharing of all data and biosamples from preclinical and clinical studies ...

Update consensus on AD/ADRD nomenclature necessary to identify target populations for intervention research...

Convene an advisory meeting of relevant stakeholders to develop a consensus regarding eliminating barriers to sharing, integrating, and reuse of data...

Alter institutional practices that impede team science and data sharing in academia

Develop and disseminate best practices for the collection, processing, and multi-omics molecular profiling of human and animal model biosamples.

Convene an advisory meeting of experts from the pharmaceutical industry, government, academia, the FDA, and the non-profit sector...

Support the development of the next generation of animal models based on the current understanding of genetic and environmental risk and protective factors for AD and related dementias…

Create infrastructure/resources for extensive characterization of existing and new animal models…

Continue to develop animal models with higher predictive validity for use in preclinical drug development…

Expand biorepository infrastructure to enable storage and rapid distribution of clinical data and biosamples…

Support the development of standardized, cost-effective, high throughput methods…

Develop improved iPSC protocols for all relevant cell types and human-based organoid model systems...

Support quantitative systems pharmacology approaches that couple biological network and pathway analyses…

Institute an expedited review track for applications focused on drug discovery, preclinical, and clinical drug development...

Create a National IRB.

Expand existing and create new integrative training programs for junior neuroscience, behavioral and social science researchers...

Leverage the power of human genetics to enable precision medicine research for AD...

Support standardized, single cell molecular profiling (genomic, proteomic, metabolomic)...

Support the development of genome-scale metabolic models to capture the heterogeneity of metabolic transitions...

Provide support for high-cost capital equipment/core facilities and staff training to make high-throughput technologies...

De-risk novel candidate targets by supporting the development of high quality, open source, target enabling tools...

Enable open drug development to generate innovative new medicines that are priced fairly for all.

Create opportunities and avenues for closer interaction between researchers developing new INDs and researchers supported through NIA's enabling infrastructure programs involved in developing data

Evaluate and update current trial funding models to ensure the ability to test novel first-in-class therapeutics in the context of the full range of expenses and time frames required for robust

Create an international FTD clinical trial network.

Develop better FTLD in vivo and cell-based model systems.

Develop models that: reproduce small vessel disease; are relevant to VCID and AD; address white and grey matter VCID; or include genetic and acquired VCID. Verify models, including via imaging.

Improve and increase training, including for individuals who are members of under-represented populations, and of different career levels of scholars who conduct health disparities research in AD/ADRD

Use data and other resources from large-scale clinical research and trials to test hypothesized mechanisms of human VCID in basic science models.

Incorporate VCID findings from basic science into the design of clinical research and trials targeting VCID-relevant cognitive impairment and dementia.

Build new animal models to advance knowledge about TDP-43 pathology in common dementias, capitalizing on lessons learned from animal models in FTLD/ALS, AD and other diseases.

Establish effective communication between NIH and NGOs

Organize a working group of stakeholders, including health disparities communities, to develop more consistent nomenclature in dementia research and care.

Generate an AD/ADRD health disparities task force